Skip to content

Implementation of Bright Light Therapy ID

Alleviation of Depressive Symptoms in People With Intellectual Disabilities

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06215235
Enrollment
105
Registered
2024-01-22
Start date
2023-10-18
Completion date
2026-05-31
Last updated
2025-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Symptoms

Keywords

Depressive symptoms, Bright light therapy, Implementation, Intellectual disability

Brief summary

Many adults with intellectual disabilities (ID) have depressive symptoms, which negatively impact their quality of life. A lot of of the non-medicinal forms of treatment are not or hardly suitable for people with ID. Bright light therapy (BLT) seems to be a good option. Earlier research has shown that BLT is applicable in this group and seems promising in terms of reducing depressive symptoms, without serious side effects. In part 1 of this project we investigate the implementation of BLT at Amarant. We will take the lessons learned into part 2 of this project: the implementation of BLT at Abrona. We will evaluate this process and the outcomes.

Interventions

OTHERBright light therapy

for 2 weeks the patient will take place for a 10.000lux lamp for 20-30 minutes.

Sponsors

Erasmus Medical Center
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Involved in the implementation of BLT (staff) OR * Involved in the prescription or application of BLT (staff/relatives) OR * receiving BLT for their depressive symptoms (patients with ID) * 18 years or older * informed consent

Exclusion criteria

* n/a

Design outcomes

Primary

MeasureTime frameDescription
Determinantsthree times during study, 3-4 months in betweenBarriers and facilitators to BLT, measured by interviews using the Consolidated Framework for Implementation Research (CFIR, Damschroder et al., 2009)
fidelitythree times during study, 3-4 months in betweenFidelity (Proctor et al., 2011) is defined as the degree to which an intervention was implemented as it was prescribed in the original protocol or as it was intended by the program developers. This will be measured by interviews and by case report study.
strategiesthree times during study, 3-4 months in betweenImplementation strategies are methods to enhance the adoption, implementation and sustainability of a policy or intervention. This will be studied with interview data and logs.
acceptabilitythree times during study, 3-4 months in betweenAcceptability (Proctor et al., 2011) is the perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory. This will be measured by interviews.
appropriatenessthree times during study, 3-4 months in betweenAppropriateness (Proctor et al., 2011) is the perceived fit, relevance, or compatibility of the innovation or evidence based practice for a given practice setting, provider, or consumer; and/or perceived fit of the innovation to address a particular issue or problem. This will be measured by interviews.
feasibility of the interventionthree times during study, 3-4 months in betweenFeasibility (Proctor et al., 2011) is defined as the extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting. This will be measured by interviews.

Secondary

MeasureTime frameDescription
Behaviour1 yearBehaviour that could be linked to depressive symptoms measured by the Aberrant Behaviour Checklist (ABC, Aman et al., 1985). It contains 58 items, each can be scored 0 to 3. Minimum score 0 and maximum score 174. Higher score means worse outcome.
Depressive symptoms1 yearDepressive symptoms measured by the Anxiety, Depression, and Mood Scale (ADAMS, Hermans et al., 2008). It contains 28 items, each can be scored 0 to 3. Minimum score 0 and maximum score 84 and higher scores mean worse outcome.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026